Kairos Pharma (KAPA) Assets Average (2024 - 2025)
Kairos Pharma's (KAPA) quarterly Assets Average came in at $6.6 million in Q4 2025, up 22.66% on a YoY basis from $5.4 million in Q4 2024, and down 9.56% quarter-over-quarter from $7.3 million in Q2 2025.
Powered by 
Analysis
Kairos Pharma (KAPA) Assets Average (2024 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has reported Assets Average for 2 consecutive years, with $6.6 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Assets Average rose 22.66% year-over-year to $6.6 million; the trailing twelve-month figure through Dec 2025 stood at $6.6 million (up 22.66% YoY), and the FY2025 full-year result was $6.2 million, up 82.8% from the prior year.
- Assets Average fell to $6.6 million in Q4 2025 per KAPA's latest filing, from $7.3 million in the prior quarter.
- Across five years, Assets Average topped out at $7.3 million in Q2 2025 and bottomed at $5.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Kairos Pharma | 30.41 Mn | 25.07 Mn | - | 6.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 6.61 Mn |
| Jun 30, 2025 | 7.31 Mn |
| Mar 31, 2025 | 6.85 Mn |
| Dec 31, 2024 | 5.39 Mn |